

Oral 11 β -HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial

R A Ajjan¹, E M A Hensor^{1b,2,3}, F Del Galdo^{2,3}, K Shams^{2,3}, A Abbas¹, R J Fairclough⁴, L Webber⁵, L Pegg⁵, A Freeman⁴, A E Taylor^{6,7}, W Arlt^{1b,6,7,8}, A W Morgan^{1,3}, A A Tahrani^{6,7,8}, P M Stewart^{3,9}, D A Russell^{1,10} and A Tiganescu^{1b,1,3}

¹Leeds Institute of Cardiovascular and Metabolic Medicine, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, ³NIHR Leeds Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK, ⁴Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, ⁵Emerging Portfolio Development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK, ⁶Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK, ⁷Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK, ⁸NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, ⁹Faculty of Medicine and Health, University of Leeds, Leeds, UK, and ¹⁰Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Correspondence should be addressed to A Tiganescu
Email
ana.tiganescu@gmail.com

Abstract

Background: Chronic wounds (e.g. diabetic foot ulcers) reduce the quality of life, yet treatments remain limited. Glucocorticoids (activated by the enzyme 11 β -hydroxysteroid dehydrogenase type 1, 11 β -HSD1) impair wound healing. **Objectives:** Efficacy, safety, and feasibility of 11 β -HSD1 inhibition for skin function and wound healing. **Design:** Investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group phase 2b pilot trial. **Methods:** Single-center secondary care setting. Adults with type 2 diabetes mellitus without foot ulcers were administered 400 mg oral 11 β -HSD1 inhibitor AZD4017 ($n = 14$) or placebo ($n = 14$) bi-daily for 35 days. Participants underwent 3-mm full-thickness punch skin biopsies at baseline and on day 28; wound healing was monitored after 2 and 7 days. Computer-generated 1:1 randomization was pharmacy-administered. Analysis was descriptive and focused on CI estimation. Of the 36 participants screened, 28 were randomized. **Results:** Exploratory proof-of-concept efficacy analysis suggested AZD4017 did not inhibit 24-h *ex vivo* skin 11 β -HSD1 activity (primary outcome; difference in percentage conversion per 24 h 1.1% (90% CI: -3.4 to 5.5) but reduced systemic 11 β -HSD1 activity by 87% (69–104%). Wound diameter was 34% (7–63%) smaller with AZD4017 at day 2, and 48% (12–85%) smaller after repeat wounding at day 30. AZD4017 improved epidermal integrity but modestly impaired barrier function. Minimal adverse events were comparable to placebo. Recruitment rate, retention, and data completeness were 2.9/month, 27/28, and 95.3%, respectively. **Conclusion:** A phase 2 trial is feasible, and preliminary proof-of-concept data suggests AZD4017 warrants further investigation in conditions of delayed healing, for example in diabetic foot ulcers.

Significance statement

Stress hormone activation by the enzyme 11 β -HSD type 1 impairs skin function (e.g. integrity) and delays wound healing in animal models of diabetes, but effects in human skin were previously unknown. Skin function was evaluated in response to treatment with a 11 β -HSD type 1 inhibitor (AZD4017), or placebo, in people with type 2 diabetes. Importantly, AZD4017 was safe and well tolerated. This first-in-human randomized, controlled, clinical trial found

novel evidence that 11 β -HSD type 1 regulates skin function in humans, including improved wound healing, epidermal integrity, and increased water loss. Results warrant further studies in conditions of impaired wound healing, for example, diabetic foot ulcers to evaluate 11 β -HSD type 1 as a novel therapeutic target for chronic wounds.

*European Journal of
Endocrinology*
(2022) **186**, 441–455

Introduction

Chronic, non-healing wounds (e.g. diabetic foot ulcers) are a common and worldwide health problem of substantial medical and socioeconomic importance (1). Costs for wound care in the UK are estimated to be £2.03 to £3.8 million per 100 000 population (2, 3). The profound atrophic effects of glucocorticoids (GC) on human skin structure and function are well documented, including increased transepidermal water loss (TEWL), skin thinning, and delayed wound healing (4, 5, 6, 7, 8, 9, 10, 11). 11 β -hydroxysteroid dehydrogenase (11 β -HSD) isozymes regulate local GC availability independently of circulating levels (12). In the skin, 11 β -HSD1 is widely expressed and induced by GC in a forward-feedback manner (13, 14).

11 β -HSD1 activity increases during wound healing (15) and 11 β -HSD1 inhibition improves wound healing in preclinical models of GC excess, aging, and diabetes (13, 16, 17, 18). Therefore, 11 β -HSD1 inhibition may aid wound healing, particularly in conditions associated with increased systemic GC levels, such as diabetes (19, 20). However, the ability of systemic 11 β -HSD1 inhibitors to regulate skin function in humans is unknown.

We conducted this randomized controlled trial to evaluate the effect of 11 β -HSD1 inhibition on skin function and wound healing in patients with type 2 diabetes mellitus.—

Patients and methods

We have summarized the trial methods in brief here but for full details please refer to the final approved trial protocol provided in Supplementary data 1 (see section on [supplementary materials](#) given at the end of this article).

Study approval

Informed consent was obtained after the nature and possible consequences of the study had been explained. Full ethical approval was acquired from North West

Greater Manchester Central Research Ethics Committee 17/NW/0283 before initiation of recruitment. The reported investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008.

Study design

This was a randomized, double-blind, parallel-group, placebo-controlled, phase 2 pilot trial in people with type 2 diabetes. Participants were recruited between March 28, 2018, and January 23, 2019 (first to last randomized participant telephone invitations), and the last participant's last follow-up call (telephone discharge) was on April 3, 2019. A total of 28 participants (22 male and 6 female) were randomized, and 27 completed the 35-day oral AZD4017 or placebo treatment.

Selection of sample size

Published guidance for pilot studies recommended a sample size of 12 participants per arm (21). To achieve this sample size, the study was designed to randomize 15 participants per arm to allow for a 20% drop-out rate.

Data monitoring

Data monitoring was carried out during the trial by the study management team and the sponsor. Independent oversight of the study, including interim safety monitoring, was conducted by an independent data monitoring and ethics committee.

Randomization and blinding

Participants and the study team were blinded to the randomization process, and other blinding procedures included mitigation of accidental unblinding, semi-blind interim safety analyses, and independent data monitoring and ethics committee oversight. Dosing compliance was

monitored by the completion of diary cards by participants and by counting the number of tablets remaining at each study visit.

Treatments and withdrawal criteria

Participants received either oral AZD4017 (400 mg) or matched oral placebo twice daily for 35 days. For full treatment and compliance details, and AZD4017 withdrawal criteria, please refer to the protocol (Supplementary data 1).

Study endpoints

The primary endpoint was 24-h 11β -HSD1 activity in skin (efficacy) at baseline and day 28. Pre-specified secondary endpoints were:

- Systemic 11β -HSD1 activity at baseline and day 35
- AZD4017 quantification in skin at day 28 and in plasma at day 35
- Safety variables at baseline and days 7, 28, 35, and 42
- Urinary cortisol to cortisone metabolite analysis at baseline and day 35 (to assess systemic GC levels)
- Skin function variables at baseline and days 2, 7, 28, 30, and 35
- Feasibility variables throughout the study

Wound healing

All individuals underwent two full-thickness 3-mm skin punch biopsies at baseline, repeated in the contralateral arm on day 28; wound healing was assessed on days 2 and 7 post-wounding (treatment days 2, 7, 30, and 35).

Statistical analysis

A detailed standalone statistical analysis plan (SAP) was developed and finalized before breaking of the blind and processing of primary outcome samples.

In this pilot study, the analysis was descriptive throughout, so no inferential hypotheses were formally tested. As pre-specified in the SAP, analysis followed published recommendations, which state that the focus in pilot trials should be on descriptive statistics and estimation using a range of CIs other than 95% and interpreting these using the minimum clinically important difference (22).

For each outcome, differences were adjusted for gender, age, baseline glycosylated hemoglobin A1c (HbA1c), and (where applicable) the baseline value of the outcome.

Primary two-sided 90% CIs were supplemented with CIs ranging from 75 to 95%, in line with recommendations. Adjusted differences were obtained via regression modeling; linear regression was used unless data did not meet the model assumptions and a suitable transformation could not be found. As pre-specified in the SAP, in these instances quantile (median) regression was used instead; this estimates the difference in the medians instead of the means, makes fewer assumptions about the data, and is less sensitive to outliers than linear regression.

Because minimum clinically important differences have not been established in this population for the outcomes investigated, we additionally reported percentage differences relative to the mean or median with placebo as a guideline. Analyses were conducted in Stata 16.1 (StataCorp 2019). For further details, see Supplementary data 2.

Results

A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in Fig. 1. In addition to the main findings, Supplementary data 3 presents full descriptive summaries of efficacy (Supplementary Table 1) and laboratory safety variables (Supplementary Table 2), compliance data (Supplementary Table 3), unadjusted differences in primary and secondary efficacy outcomes (Supplementary Table 4), sensitivity analyses after outlier removal (Supplementary Table 5), unadjusted and adjusted changes from baseline (Supplementary Tables 6 and 7), additional pre-specified sensitivity analyses (Supplementary Tables 8, 9, and 10), correlations between AZD4017 compliance and efficacy outcomes (Supplementary Table 11), full laboratory safety data (Supplementary Tables 12, 13, 14, and 15) and sample sizes for future trials (Supplementary Table 16).

Differences between groups are presented with 90% CI, unless otherwise stated.


Participant demographics and baseline variables

The two randomized arms were well balanced for participant demographics, baseline efficacy, and laboratory safety variables (Table 1).

Efficacy

Primary outcome skin 11β -HSD1 activity

Median 11β -HSD1 activity (% conversion per 24 h) by radioassay at day 28 was similar in both treatments after

**Figure 1**

CONSORT flow diagram. Progress, from screening to study completion, of participants in the double-blind, randomized, placebo-controlled pilot trial comparing 35-day oral AZD4017 treatment with placebo in adults with type 2 diabetes. A total of 300 prospective participants were screened. Eight of the 36 individuals enrolled in the study were not randomized because they did not meet eligibility criteria, and 27 of 28 participants who were randomized completed the study.

adjustment for baseline activity, baseline HbA1c, age, and sex. The median was 11.8% with placebo and 12.8% with AZD4017, with a difference of 1.1% (−3.4, 5.5, Fig. 2A, and Table 2). This outcome was unaffected in sensitivity analysis after the removal of two baseline samples that were considered unreliable.

Another sensitivity analysis that used an alternative ELISA method had an acceptable correlation with the radioassay method at baseline (Spearman's $\rho=0.70$) but not at day 28 (Spearman's $\rho=0.19$) (Table 3 and Supplementary Fig. 1). ELISA results were consistent with the radioassay method. Therefore, the pilot data offered no proof-of-concept of 11 β -HSD1 inhibition by AZD4017 in skin, in contrast to the systemic effects detailed below.

Systemic 11 β -HSD1 activity

Systemic 11 β -HSD1 activity was inferred from 24 h urinary steroid metabolite ratios tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone ((THF+alloTHF)/THE) by liquid chromatography-tandem mass spectrometry (23). In

contrast to the skin, systemic 11 β -HSD1 activity was lower with AZD4017; the adjusted median was 1.00 with placebo and 0.13 with AZD4017, and the difference was −0.87 (−1.04, −0.69) (Fig. 2B and Table 2). All supplementary CIs up to 95% excluded 0, suggesting that median systemic 11 β -HSD1 activity may be at least 69% (median 87%) lower in participants taking AZD4017. As anticipated, the results showed no evidence that urinary cortisol/cortisone ratio (a measure of systemic 11 β -HSD2 activity that deactivates cortisol to cortisone; unplanned analysis) was affected by AZD4017. The adjusted median was 0.71 with placebo and 0.65 with AZD4017; the difference was −0.06 (−0.19, 0.07, Fig. 2C).

Wound healing

Based on maximal granulation tissue width (a marker of early wound healing), the mean wound gap 2 days after each of the separate biopsies was lower with AZD4017 at all levels of confidence. The mean difference was −0.52 mm (−0.95 mm, −0.10 mm) at day 2 and −0.65 mm (−1.15 mm, −0.016 mm) at day 30, corresponding to a 7–63% (mean 34%) and 12–85% (mean 48%) narrower wound gap diameter, respectively, with AZD4017 (Fig. 3A, B and Table 2). Representative wound healing images for participants treated with placebo and AZD4017 are presented in Fig. 3C.

Based on maximal clot depth (a marker of late wound healing), the data showed no indication of a difference on either day 7 or day 35 (Table 2).

Epidermal barrier function

The epidermal barrier is essential in guarding against water loss and infection. Barrier defects are associated with a range of skin pathologies, for example, atopic dermatitis (24), and functions are regulated by GC in a complex manner (25), but the role of 11 β -HSD1 is unknown.

TEWL, the gold-standard measure of epidermal barrier function, was on average 33% higher with AZD4017 on day 35 (Fig. 3D and Table 2), but 90% CI included 0. At lower levels of confidence, resting TEWL was higher with AZD4017, and in sensitivity analysis (which excluded potentially unreliable values), the 90% CI was 3–88%.

Epidermal integrity

Epidermal integrity contributes to skin resilience against mechanical damage (wounding), measured by resistance to sequential tape stripping of epidermal layers.

Table 1 Baseline demographics, primary and secondary efficacy outcomes, and safety variables of the population under study (full analysis set). Data are presented as mean \pm s.d. or median (Q1 and Q3).

Variable	Placebo	AZD4017	Total
<i>n</i>	14	14	28
Demographics			
Age			
Mean \pm s.d.	60.3 \pm 13.4	60.1 \pm 14.5	60.2 \pm 13.7
Range	31–84	28–75	28–84
Male, <i>n/N</i> (%)	12/14 (86)	10/14 (71)	22/28 (79)
Primary outcome			
Skin 11 β -HSD1 activity (% conversion/24 h)			
Radioassay	15.3 (11.6, 18.4)	10.7 (9.4, 17.4)	13.6 (9.8, 17.9)
ELISA	6.8 (5.5, 15.6)	6.4 (4.2, 8.5)	6.8 (4.8, 10.7)
Secondary outcomes			
Systemic 11 β -HSD1 activity			
Urinary (THF+alloTHF)/THE ratio	1.0 (0.8, 1.2)	1.0 (0.8, 1.1)	1.0 (0.8, 1.1)
Cortisol (μ g/24 h)	68.5 (40.0, 101.0)	75.5 (48.0, 84.0)	74.5 (47.5, 94.0)
Epidermal barrier TEWL (g/h/m ²)*	2.1 \pm 0.4 (8.2)	2.2 \pm 0.3 (9.1) [†]	2.2 \pm 0.4 (8.6) [†]
Epidermal integrity (tape strips)*	3.8 \pm 0.4 (44.5)	3.9 \pm 0.5 (50.5) [†]	3.9 \pm 0.4 (47.5) [†]
Epidermal thickness (μ m)	62.8 (54.5, 69.2)	65.7 (60.7, 69.3)	63.8 (58.4, 69.3)
Skin hydration (AU)	40.5 (34.5, 46.2)	40.4 (36.7, 45.5)	40.5 (36.1, 45.8)
Sudomotor nerve function (μ S)			
Left hand	54.0 (47.0, 63.0)	57.5 (39.0, 71.0)	56.0 (46.5, 68.5)
Right hand	54.0 (47.0, 60.0)	56.5 (41.0, 67.0)	56.0 (45.5, 61.5)
Hands	53.8 (48.0, 60.5)	56.8 (40.0, 70.5)	56.8 (47.3, 65.0)
Left foot	65.5 (46.0, 78.0)	79.0 (63.0, 84.0)	74.5 (57.0, 81.5)
Right foot	69.5 (48.0, 79.0)	77.0 (69.0, 82.0)	74.0 (54.5, 79.0)
Feet	67.5 (44.5, 76.5)	78.0 (64.0, 83.5)	75.0 (55.8, 79.8)
Overall	61.0 (46.8, 67.8)	66.6 (63.3, 71.3)	64.6 (50.3, 69.8)
Safety variables			
BMI (kg/m ²)	33.67 \pm 13.47	35.05 \pm 5.68	34.36 \pm 10.17
Waist-hip ratio	0.98 \pm 0.08	1.03 \pm 0.08	1.01 \pm 0.08
HbA1c (mmol/mol)	72.29 \pm 19.43	66.00 \pm 14.91	69.14 \pm 17.29
Blood pressure (mmHg)			
Systolic	135.71 \pm 21.01	140.43 \pm 12.02	138.07 \pm 16.97
Diastolic	83.86 \pm 8.91	72.64 \pm 9.96	78.25 \pm 10.89
Full blood count			
Hemoglobin (g/L)	139.21 \pm 14.12	139.43 \pm 11.35	139.32 \pm 12.57
White blood cells ($\times 10^9$ /L)	6.46 \pm 2.55	7.34 \pm 2.04	6.90 \pm 2.31
Platelets ($\times 10^9$ /L)	218.71 \pm 61.85	273.14 \pm 81.37	245.93 \pm 76.15
Red blood cells ($\times 10^{12}$ /L)	4.84 \pm 0.49	4.71 \pm 0.48	4.78 \pm 0.48
Mean corpuscular volume (fL)	88.43 \pm 4.64	91.21 \pm 6.96	89.82 \pm 5.98
Hematocrit (packed cell volume)	0.43 \pm 0.04	0.43 \pm 0.03	0.43 \pm 0.03
Mean corpuscular hemoglobin (pg)	28.82 \pm 2.09	29.74 \pm 2.47	29.28 \pm 2.29
Corpuscular hemoglobin (g/L)	325.57 \pm 10.43	326.64 \pm 8.29	326.11 \pm 9.26
Red blood cell distribution width (%)	13.88 \pm 0.98	14.12 \pm 1.10	14.00 \pm 1.03
Lipid profile			
High density lipoprotein (mmol/L)	1.24 \pm 0.31	1.19 \pm 0.27	1.21 \pm 0.29
Cholesterol (mmol/L)	4.36 \pm 1.13	3.95 \pm 0.75	4.15 \pm 0.97
Triglycerides (mmol/L)	1.68 \pm 0.74	2.02 \pm 1.02	1.85 \pm 0.89
Liver function			
Albumin (g/L)	39.43 \pm 2.56	39.50 \pm 2.44	39.46 \pm 2.46
Bilirubin (μ mol/L)	8.93 \pm 2.97	8.14 \pm 2.82	8.54 \pm 2.87
Alkaline phosphatase (U/L)	80.43 \pm 23.76	85.07 \pm 26.08	82.75 \pm 24.59
Alanine aminotransferase (IU/L)	24.64 \pm 7.10	27.43 \pm 10.91	26.04 \pm 9.14
Aspartate aminotransferase (IU/L)	21.00 \pm 4.95	22.64 \pm 5.50	21.82 \pm 5.20
Gamma-glutamyl transpeptidase (IU/L)	41.86 \pm 33.87	39.29 \pm 29.87	40.57 \pm 31.37
Kidney functioL			
eGFR (mL/min/1.73 m ²)	81.86 \pm 9.69	79.21 \pm 13.59	80.54 \pm 11.66
Sodium (mmol/L)	138.93 \pm 2.06	140.71 \pm 5.47	139.82 \pm 4.15

(Continued)

Table 1 Continued.

Variable	Placebo	AZD4017	Total
Potassium (mmol/L)	4.46 ± 0.33	4.63 ± 0.41	4.55 ± 0.37
Urea (mmol/L)	6.96 ± 2.81	7.25 ± 2.17	7.10 ± 2.47
Creatinine (µmol/L)	76.64 ± 15.36	76.21 ± 20.04	76.43 ± 17.52
Adrenal function			
Testosterone (nmol/L)	11.10 ± 6.25	6.97 ± 5.48	9.04 ± 6.14
DHEAS (µmol/L)	3.53 ± 2.19	2.91 ± 1.69	3.22 ± 1.95
Thyroid function			
Free thyroxine (pmol/L)	14.86 ± 2.20	15.73 ± 1.58	15.30 ± 1.93
Thyroid stimulating hormone (mIU/L)	1.74 ± 0.66	1.72 ± 0.63	1.73 ± 0.64

*values are log mean ± s.d. and values in parentheses is the geometric mean; †*n* = 13; ‡*n* = 27.
n, number non-missing; Q1, first quartile; Q3, third quartile.

The number of tapes required to achieve the same degree of barrier disruption (TEWL of 40–50 g/h/m²) was 7–91% (mean 43%) higher with AZD4017 (Fig. 3E and Table 2), equivalent to an additional 16.8 tapes.

Epidermal barrier recovery

The first set of post-disruption recovery measurements, collected between baseline and day 7, provided no proof of concept for a difference in TEWL (Table 2).

The second set of post-disruption recovery measurements, collected between days 28 and 35, indicated higher TEWL with AZD4017 at 3 h and 48 h, at 80–85% confidence, although the CIs were wide (Fig. 3F, G and Table 2). By 168 h after disruption, there was no difference (Table 2).

Together with pre-disruption epidermal barrier findings, these preliminary results suggest a novel role for skin 11β-HSD1 in the maintenance of epidermal barrier homeostasis, which would require confirmation in larger future trials.

Epidermal thickness

Although the observed median epidermal thickness was greater with AZD4017 at day 35, median skin thickness could be between 8% thinner and 26% thicker with AZD4017 (Table 2).

Skin hydration

Dry skin is less resistant to wounding and is common in people with diabetes (26).

Although the observed median hydration was higher with AZD4017, consistent with proof of concept, hydration could be between 7% lower and 37% higher in those receiving AZD4017 (Table 2).

Sudomotor nerve function

Reduced sudomotor nerve function is a leading cause of chronic foot ulcers (27) but regulation by GC is unknown.

Averaged across all sites, there was no proof of concept of a difference in sudomotor function; results suggested function could be between 14% worse and 10% better with AZD4017 (Table 2). There was also no proof of concept (and CIs included only modest potential differences in either direction) when results were averaged for hands and feet separately.

Sensitivity analyses indicated worse foot sudomotor function with AZD4017 at 75% confidence, but all other results from this additional analysis were consistent with the main findings.

Compliance

Mean diary card compliance was >97.9% in both arms at all visits and >99.6% at day 35. Mean treatment compliance at each visit was >95.2% in both arms and >97.9% at day 35; overall treatment compliance was 84–101% with placebo and 93–101% with AZD4017. Drug exposure data in plasma and skin did not indicate any discrepancies between reported compliance rates and actual exposure, which suggests that participants had correctly adhered to their assigned treatment regimen.

As anticipated, AZD4017 levels in day 28 skin biopsies and day 35 plasma samples correlated moderately (Spearman's rho=0.54; Supplementary Fig. 2), further validating drug tissue penetration.

Correlations between compliance and efficacy outcomes

In those taking AZD4017, several outcome measures displayed a possible association with compliance (absolute rho >0.3), including negative associations with 11β-HSD1




Figure 2

Efficacy outcome measures. Population: Full analysis set. (A) Box plots of observed skin 11β -HSD1 activity (percent conversion (conv) per 24 h measured by radioassay) (left panel) and adjusted differences between placebo (PCB) and AZD4017 (AZD) medians at day 28 with CIs estimated in imputed data (right panel). (B) Box plots of observed urinary (THF+alloTHF)/THE ratio (left panel), indicative of systemic 11β -HSD1 activity and adjusted differences between medians at day 35 with CIs estimated in imputed data (right panel). (C) Means and 90% CIs for observed urinary cortisol/cortisone (F/E) ratio (left panel), indicative of systemic 11β -HSD2 activity and adjusted differences between means at day 35 with CIs estimated in observed data (right panel). Solid lines indicate no difference.

activity (skin activity measured by ELISA and systemic activity measured by urinary (THF+alloTHF)/THE ratios) and positive associations with TEWL and skin hydration.

Safety

Biopsy and ECG

Biopsy findings did not raise any clinical concerns, and all passed a physical inspection. No incidents of

infection were observed. Participants did not report any significant pain or discomfort from the biopsies, which all healed well.

No participants remaining in the trial at day 42 (13 with placebo and 14 with AZD4017) showed clinically meaningful ECG anomalies.

Longitudinal laboratory safety data

With AZD4017 (Table 3) DHEAS was higher on days 7, 28, 35, and 42; total cholesterol was lower on days 7, 28, and 35; high-density lipoprotein was lower on day 35, and systolic blood pressure was lower on day 28 (Fig. 4A, B, C, D and Table 3).

Apart from some small differences which were not considered to be clinically relevant, the remaining variables did not differ (Fig. 4E, F, G, H, I and Table 3).

Although several laboratory findings (with both treatments) were above or below accepted clinically normal limits, few warranted further investigation or intervention by the study team, and none resulted in treatment withdrawal.

Adverse events

Thirty-seven individual adverse events (AEs) occurred, of which 13 were with placebo and 24 with AZD4017 (Table 4). When recurring instances of the same AE within a participant were counted as a single AE, 29 unique AEs occurred, of which 16 were with AZD4017 and 13 with placebo. Most AEs involved the gastrointestinal, nervous, or respiratory systems. Twenty-six AEs were mild and three were moderate. None of the 29 unique AEs were considered probably or definitely related to the study drug, 20 were possibly related, and 8 were unlikely to be related. AEs were broadly balanced across treatment arms, although all three moderately severe events occurred with AZD4017.

Future study power estimation

Based on power calculations from the current trial, we anticipate that 100–150 participants per arm should suffice to detect a difference of 20% or more in comparison with placebo for all outcome measures.

Feasibility

Our assessment of the study's recruitment rate, proportions meeting each eligibility criterion, the proportion of eligible

Table 2 Primary and secondary efficacy outcomes; adjusted differences. Population: Full analysis set. Multiple imputation was used to address missing data. For TEWL, integrity, wound depth, and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; differences are expressed as ratios of geometric means between groups (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used. For each variable, the comparison was adjusted for the variable's baseline value (this was not available for wound diameter and depth), age, sex, and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline. Between-group differences were not calculated for biopsy and plasma AZD4017 because available placebo values did not vary, and all were below the detection limit.

Variable	Observed			Estimated median*			Difference*	90% CI
	Placebo		n	AZD4017		n		
	Median (Q1, Q3)	n		Median (Q1, Q3)	n			
Primary outcome								
Skin 11 β -HSD1 activity (% conversion/24 h): day 28								
Radioassay	12.0 (8.9, 14.5)	13	12.7 (8.8, 15.6)	14	11.8	12.8	1.1	(-3.4, 5.5)
ELISA	5.6 (1.0, 7.6)	13	4.3 (3.1, 5.0)	14	4.9	4.3	-0.5	(-3.8, 2.7)
Secondary outcomes								
Systemic 11 β -HSD1 activity: day 35								
Urinary (HF+alloTHF)/THE ratio	0.89 (0.88, 1.24)	13	0.10 (0.08, 0.12)	13	1.00	0.13	-0.87	(-1.04, -0.69)
Cortisol (μ g/24h)	55.0 (47.0, 120.0)	13	62.0 (52.0, 73.0)	13	61.6	66.9	5.3	(-30.2, 40.7)
Epidermal thickness (μ m)	57.5 (55.7, 67.3)	13	66.3 (60.6, 74.4)	12	61.2	66.8	5.6	(-4.9, 16.0)
Skin hydration (A.U)	40.5 (29.4, 46.0)	12	45.3 (37.0, 46.5)	12	38.0	43.7	5.7	(-2.8, 14.1)
Sudomotor (nerve) function (μ S): day 35								
Left hand	58.0 (48.0, 63.0)	13	64.0 (59.0, 72.0)	13	55.3	65.7	10.4	(-1.8, 22.6)
Right hand	55.0 (51.0, 60.0)	13	63.0 (57.0, 69.0)	13	55.6	60.6	5.0	(-6.7, 16.8)
Hands	57.5 (49.5, 61.0)	13	63.5 (59.0, 70.5)	13	55.8	63.0	7.3	(-4.8, 19.3)
Left foot	70.0 (61.0, 76.0)	13	80.0 (64.0, 82.0)	13	75.5	68.5	-7.0	(-18.4, 4.3)
Right foot	65.0 (63.0, 75.0)	13	80.0 (68.0, 82.0)	13	73.0	68.9	-4.1	(-13.2, 5.1)
Feet	68.5 (62.0, 75.0)	13	80.0 (66.0, 82.5)	13	73.8	69.3	-4.5	(-14.5, 5.4)
Overall	59.8 (53.8, 68.0)	13	70.8 (64.5, 73.0)	13	65.0	63.7	-1.3	(-9.2, 6.6)
AZD4017 (nmol/L)								
Biopsy: day 28	<5 (<5, <5)	13	1570 (876, 2440)	14				
Plasma: day 35	<5 (<5, <5)	7	6490 (2960, 9040)	12				
Wound healing (mm) after day 0 biopsies								
Diameter: day 2	1.49 (0.72)	14	0.98 (0.70)	14	1.51	0.98	-0.52	(-0.95, -0.10)
Depth: day 7	0.60 (0.23)	14	0.59 (0.16)	14	0.60	0.59	-0.01	(-0.15, 0.13)
Wound healing after day 28 biopsies								
Diameter: day 30	1.44 (0.70)	11	0.65 (0.49)	12	1.35	0.70	-0.65	(-1.15, 0.16)
Depth: day 35	0.60 (0.17)	13	0.54 (0.21)	12	0.59	0.56	-0.03	(-0.16, 0.09)
Epidermal barrier TEWL (g/h/m ²): day 35	1.9 (0.4): 7.0	13	2.2 (0.5): 8.9	12	6.9	9.2	1.33	(0.97, 1.82)
Epidermal integrity (tape strips): day 28	3.6 (0.6): 37.9	13	4.0 (0.4): 55.6	14	39.0	55.8	1.43	(1.07, 1.91)
Epidermal barrier recovery TEWL (g/h/m²) after day 0 disruption								
Hour 3	3.6 (0.3): 34.9	14	3.4 (0.2): 30.8	12	35.1	32.0	0.91	(0.76, 1.09)
Hour 48	3.0 (0.3): 19.8	14	3.1 (0.4): 21.3	11	20.4	20.6	1.01	(0.79, 1.28)
Hour 168	2.6 (0.3): 13.5	13	2.8 (0.7): 16.1	13	14.1	15.6	1.11	(0.76, 1.62)
Epidermal barrier recovery TEWL (g/h/m²) after day 28 disruption								
Hour 3	3.2 (0.5): 23.8	13	3.4 (0.3): 29.8	14	23.0	30.7	1.33	(0.99, 1.79)
Hour 48	2.7 (0.4): 14.4	13	2.9 (0.4): 18.2	14	14.6	18.4	1.26	(0.94, 1.67)
Hour 168	2.3 (0.4): 10.0	13	2.4 (0.4): 10.8	12	10.1	10.8	1.07	(0.79, 1.44)

*Estimated using multiple imputation, adjusted for baseline value (if applicable), age, sex, and baseline HbA1c.

candidates consenting to take part, and data completeness found that a future confirmatory trial is feasible.

Discussion

Our double-blind, randomized, placebo-controlled, parallel-group pilot clinical trial provides preliminary evidence that wounds were smaller and skin integrity was greater in people with type 2 diabetes with systemic 11 β -HSD1 inhibition. This finding potentially represents a major advance in the development of 11 β -HSD1 inhibitors as novel therapies for diabetic ulcers. Nevertheless, all findings from this pilot study are considered exploratory, which requires confirmation in an adequately powered phase 2 trial.

Studies previously demonstrated effective 11 β -HSD1 inhibition in mouse skin (13, 16), but this had not been explored in humans. In this pilot study, data on our primary outcome measure failed to show 11 β -HSD1 inhibition in the skin. The absence of skin 11 β -HSD1 inhibition was not due to lack of exposure *in situ* because AZD4017 levels in skin correlated with plasma levels, albeit at lower concentrations. Alternatively, ineffective AZD4017 efficacy *ex vivo* (low target affinity) or insufficient assay sensitivity (as baseline 11 β -HSD1 activity was relatively low) may explain this finding. In this situation, the analysis plan stipulated that differences in secondary outcomes were only to be interpreted if AZD4017 inhibited systemic 11 β -HSD1 activity. Indeed, we found AZD4017 reduced [THF+alloTHF]/THE ratios and elevated DHEAS. This finding is consistent with that of other selective 11 β -HSD1 inhibitor trials, including AZD4017 (28, 29, 30, 31, 32). Importantly, 11 β -HSD2 activity was unaffected by AZD4017 (23, 33).

Our secondary outcomes, although exploratory, offer a series of novel insights into the potential effects of 11 β -HSD1 inhibition on skin function. Optical coherence tomography is a validated method for the non-invasive assessment of wound healing (34), and this is the first application in a randomized controlled trial. Our finding of improved early granulation tissue healing in day 2 wounds (across all CIs) with only 2 days of AZD4017 treatment is very promising, especially as overall healing in this cohort was normal, and participants' diabetes was well managed. Further, this effect was greater after 30 days of treatment, suggesting improved efficacy with increased AZD4017 exposure.

By day 7 after wounding, early granulation tissue remodeling was complete in all participants and no

effect with AZD4017 was detected, potentially because we measured clot depth, rather than volume. In a subsequent study, we developed a new machine learning method for automated volumetric quantification of key morphological features of wound healing using the optical coherence tomography scans from this clinical trial, which further supports our finding that AZD4017 promotes wound healing (35). These novel pilot human data are consistent with the known deleterious effects of GC on wound healing (36) and with preclinical evidence of improved healing by 11 β -HSD1 inhibition in animal models of stress, obesity, GC excess, and aging from our group and others (13, 16, 17, 18).

We also found that AZD4017 increased epidermal integrity, an improvement compared to the greater epidermal integrity of young vs aged skin (37). This is supported by studies demonstrating reduced skin integrity after human psychological stress (38) or exogenous GC treatment (39) and strengthens the basis for further development of AZD4017 to improve skin function.

Provisional evidence of modest impairments in epidermal barrier function and recovery with AZD4017 was also observed in our study. GCs are known to both impair and promote epidermal barrier function, the former during exogenous GC treatment (39, 40, 41) and the latter during endogenous GC excess (25). Our results are in agreement, showing for the first time that endogenous cortisol may promote epidermal barrier function via 11 β -HSD1.

GCs impair healing through multiple mechanisms, for example, by inhibiting keratinocyte re-epithelialization whilst promoting keratinocyte differentiation (essential for barrier function) (9), supporting our findings of improved wound healing and impaired barrier function by AZD4017. Future 11 β -HSD1 inhibitor trials should monitor the epidermal barrier, particularly in participants with compromised function (e.g. atopic dermatitis). Other key mechanisms of wound healing defect in aging and diabetes include progenitor (stem) cell recruitment and angiogenesis (42), both associated with GC excess (43, 44). Abnormal immune cell function is also implicated in chronic wound etiology, for example, increased neutrophil extracellular trap formation (45) but the role of GC in this process is unknown. Such detailed mechanistic studies were beyond the scope of this pilot trial and regulation of these pathways by 11 β -HSD1 remains an important area for future research.

Peripheral neuropathy is a serious complication in diabetes but regulation by GC is unknown. Nerve function was determined by sudomotor analysis, as previously described (27). In our study, AZD4017 did not affect nerve

Table 3 Longitudinal laboratory safety variables; adjusted differences. Population: safety set. All point estimates and CIs were estimated using linear regression in imputed data ($n = 14$ for placebo, $n = 14$ for AZD4017).

Variable	Difference* AZD4017-placebo (90% CI)			
	Day 7	Day 28	Day 35	Day 42
BMI (kg/m ²)	N/A	N/A	0.41 (−0.51, 1.34)	N/A
Waist-hip ratio	N/A	N/A	0.02 (−0.01, 0.05)	N/A
HbA1c (mmol/mol)	0.18 (1.51, 1.88)	2.17 (0.64, 4.99)	0.72 (−3.64, 5.09)	2.42 (−2.38, 7.22)
Blood pressure (mmHg)				
Systolic	N/A	N/A	−14.74 (−23.00, −6.47)	0.77 (−6.58, 8.11)
Diastolic	N/A	N/A	−2.43 (−7.67, 2.80)	2.09 (−6.77, 10.95)
Full blood count				
Hemoglobin (g/L)	0.67 (−2.12, 3.45)	−0.98 (−4.13, 2.17)	0.64 (−3.96, 5.24)	2.07 (−1.62, 5.76)
White blood cells ($\times 10^9/L$)	0.54 (−0.14, 1.22)	−0.40 (−0.87, 0.08)	−0.31 (−0.96, 0.34)	0.33 (−0.41, 1.07)
Platelets ($\times 10^9/L$)	2.42 (−13.65, 18.50)	13.32 (−9.56, 36.20)	−0.91 (−25.20, 23.37)	1.47 (−16.74, 19.68)
Red blood cells ($\times 10^{12}/L$)	−0.05 (−0.17, 0.06)	−0.05 (−0.15, 0.04)	−0.02 (−0.15, 0.12)	0.15 (0.03, 0.26)
Mean corpuscular volume (fL)	0.11 (−1.83, 2.05)	0.52 (−1.49, 2.53)	−0.17 (−2.53, 2.19)	0.16 (−1.42, 1.73)
Hematocrit (packed cell volume)	−0.01 (−0.02, 0.01)	0.00 (−0.01, 0.02)	0.00 (−0.02, 0.02)	0.02 (0.00, 0.03)
Mean corpuscular hemoglobin (pg)	0.41 (0.08, 0.75)	−0.07 (−0.44, 0.31)	0.17 (−0.28, 0.62)	−0.42 (−0.95, 0.10)
Corpuscular hemoglobin (g/L)	4.91 (−1.41, 11.22)	−3.80 (−10.80, 3.21)	1.75 (−4.85, 8.35)	−5.22 (−12.18, 1.74)
Red blood cell distribution width (%)	−0.36 (−0.89, 0.18)	−0.09 (−0.49, 0.31)	0.11 (−0.28, 0.51)	−0.21 (−0.68, 0.26)
Lipid profile				
High-density lipoprotein (mmol/L)	−0.06 (−0.14, 0.02)	−0.08 (−0.16, 0.00)	−0.13 (−0.21, −0.05)	0.05 (−0.07, 0.16)
Cholesterol (mmol/L)	−0.42 (−0.60, −0.23)	−0.46 (−0.79, −0.12)	−0.51 (−0.87, −0.15)	−0.10 (−0.54, 0.34)
Triglycerides (mmol/L)	−0.14 (−0.67, 0.40)	−0.19 (−0.56, 0.18)	−0.48 (−1.21, 0.24)	0.02 (−0.51, 0.55)
Liver function				
Albumin (g/L)	0.37 (−0.82, 1.55)	−0.37 (−1.82, 1.09)	−0.01 (−1.60, 1.59)	0.40 (−0.59, 1.38)
Bilirubin ($\mu\text{mol/L}$)	0.93 (−1.14, 3.00)	0.60 (−0.89, 2.09)	−0.64 (−3.01, 1.73)	0.35 (−1.17, 1.87)
Alkaline phosphatase (U/L)	−6.00 (−12.44, 0.44)	−12.39 (−20.21, −4.56)	−13.09 (−20.43, −5.75)	−5.65 (−15.25, 3.95)
Alanine aminotransferase (IU/L)	1.16 (−1.84, 4.15)	−1.96 (−4.94, 1.03)	−1.64 (−5.88, 2.61)	0.78 (−3.00, 4.56)
Aspartate aminotransferase (IU/L)	0.46 (−2.29, 3.21)	0.12 (−1.81, 2.05)	−0.04 (−2.52, 2.45)	2.21 (−1.02, 5.44)
Gamma-glutamyl transpeptidase (IU/L)	0.76 (−2.83, 4.35)	−10.28 (−14.96, −5.60)	−11.97 (−22.80, −1.15)	−9.55 (−14.88, −4.22)
Kidney function				
eGFR (mL/min/1.73 m ²)	−3.18 (−8.30, 1.94)	−2.19 (−5.38, 1.01)	0.27 (−4.57, 5.10)	1.62 (−2.77, 6.01)
Sodium (mmol/L)	0.10 (−1.23, 1.44)	0.16 (−0.98, 1.29)	−1.19 (−3.21, 0.82)	−1.25 (−2.42, −0.07)
Potassium (mmol/L)	−0.31 (−0.58, −0.03)	0.18 (−0.06, 0.43)	0.01 (−0.22, 0.25)	−0.04 (−0.31, 0.22)
Urea (mmol/L)	0.13 (−0.79, 1.05)	−0.35 (−1.31, 0.61)	−0.52 (−1.88, 0.83)	0.02 (−1.04, 1.08)
Creatinine ($\mu\text{mol/L}$)	7.43 (0.79, 14.08)	3.43 (−0.98, 7.85)	1.78 (−5.65, 9.22)	−1.58 (−8.24, 5.07)
Adrenal function				
Testosterone (nmol/L)	−0.63 (−2.52, 1.25)	−1.06 (−2.58, 0.45)	−0.40 (−2.66, 1.85)	1.12 (−1.20, 3.45)
DHEAS ($\mu\text{mol/L}$)	2.30 (1.52, 3.08)	2.86 (2.09, 3.64)	2.16 (1.29, 3.04)	1.09 (0.43, 1.75)
Thyroid function				
Free thyroxine (pmol/L)	0.50 (−0.63, 1.64)	0.51 (−0.43, 1.44)	0.65 (−0.45, 1.76)	0.79 (0.07, 1.52)
Thyroid stimulating hormone (mIU/L)	0.10 (−0.22, 0.42)	−0.20 (−0.58, 0.19)	−0.15 (−0.54, 0.23)	−0.04 (−0.46, 0.38)

*Estimated in imputed data, adjusted for baseline value, age, sex, and baseline HbA1c.

function overall or in the hands. At the lowest level of confidence, a modest impairment occurred in the feet. Therefore, future trials should also monitor nerve function to rule out any adverse effects.

We found no significant safety concerns in this small pilot study. Indeed, we found improvements in cardiovascular risk factors (notably total cholesterol and systolic blood pressure) in the AZD4017 arm. These improvements are consistent with results from other 11 β -HSD1 inhibitor trials (28, 30, 46, 47). Cardiovascular risk factors are a strong predictor of ulcers, healing, complications, and recurrence (48, 49). Therefore, oral 11 β -HSD1 inhibitors could also reduce ulcer recurrence but this

requires further studies with long-term 11 β -HSD1 inhibitor treatment. Concomitant medication use was not formally measured in this trial but warrants monitoring in these future studies.

Our study has several limitations, including the use of biopsy healing rather than ulcers, which was necessary to ensure AZD4017 was safe in acute wounds and well-managed diabetes, before application to more severe disease. Importantly, however, our approach enabled the study of wound healing in a standardized manner, where issues such as infection and ulcer chronicity that would influence healing to apply to a lesser extent, thus enabling a more focused assessment of AZD4017 impact.





Figure 3

Skin outcome measures. Population: Full analysis set. (A, B, D, E, F, and G) Means and 90% CIs for observed values (left panel) and adjusted differences between PCB and AZD means with CIs estimated in imputed data (right panel). TEWL and integrity readings were log-transformed before analysis; therefore, geometric means and ratios are provided for these variables. Solid lines indicate no difference. (C) Representative day 2 biopsy wound healing optical coherence tomography images (after 2 days of treatment). Maximal early granulation tissue width (arrow) was measured for participants treated with PCB (left panel) or AZD4017 (right panel). Wide dashes indicate dermal–epidermal junction. Scale bar: 250 μm. AZD, AZD4017; d, dermis; e, epidermis; gt, granulation tissue; PCB, placebo; TEWL, transepidermal water loss.

**Figure 4**

Longitudinal laboratory safety data.

Population: safety set. Means and 90% CIs with PCB and AZD over time in cases with data available. AZD, AZD4017; LLN, lower limit of normal (where applicable); PCB, placebo; ULN, upper limit of normal.

Although our findings are promising, the small sample size and lack of inferential testing (consistent with recommendations for pilot trials) necessitate confirmation in future trials.

Together, our findings provide justification for a powered phase 2 clinical trial in people with diabetic

foot ulcers with an established ulcer healing measure as the primary outcome. This will likely be multicenter, coordinated with routine appointments, and with randomization stratified for variables known to affect 11β -HSD1 function and wound healing (e.g. ulcer size and duration at presentation). Although requiring

Table 4 Adverse event summary. Population: safety set.

	PCB (n = 14)	AZD (n = 14)	All participants (n = 28)
AEs			
Total AEs, n (n per PY)	13 (8.3)	24 (13.8)	37 (11.1)
Unique AE, n (n per PY)	13 (8.3)	16 (9.2)	29 (8.7)
Patients with ≥ 1 AE, n (%)	8 (57)	10 (71)	18 (64)
Discontinuation due to AE, n (%)	0 (-)	0 (-)	0 (-)
AEs by SOC: total n (unique n*), n (%)			
Gastrointestinal	9 (9), 6 (43)	14 (8), 7 (50)	23 (17), 13 (46)
Infections	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Musculoskeletal	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Nervous system	1 (1), 1 (7)	6 (4), 4 (29)	7 (5), 5 (18)
Respiratory	2 (2), 1 (7)	2 (2), 1 (7)	4 (4), 2 (7)
Skin	1 (1), 1 (7)	0 (0), 0 (-)	1 (1), 1 (4)
AE severity, n*			
Mild	13	13	26
Moderate	0	3	3
AEs by relation to study drug, n*			
Not related	0	1	1
Unlikely	4	4	8
Possible	9	11	20
SAEs			
Total SAE, n	0	1	1
Patients with >1 SAE, n (%)	0 (-)	1 (7)	1 (4)

*Recurrent AEs counted once at maximum severity and relatedness reported.

AE, adverse event; PY, patient year; SAE, serious adverse events; SOC, Common Terminology Criteria for Adverse Events system order class.

confirmation, the exploratory results from this pilot trial relating to healing, skin integrity, and cardiovascular risk factors for ulcer recurrence hold promise for 11 β -HSD1 as a novel therapeutic target in wound repair.

Supplementary materials

This is linked to the online version of the paper at <https://doi.org/10.1530/EJE-21-1197>.

Declaration of interest

A A T reports grants, personal fees, and travel support from Sanofi, grants, personal fees, and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Respironics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from BHR Pharmaceuticals Ltd. AAT is currently an employee of Novo Nordisk. This work was performed before AAT becoming a Novo Nordisk employee and Novo Nordisk had no role in this study. Wiebke Arlt is the Editor in Chief of European Journal of Endocrinology. Wiebke Arlt was not involved in the review or editorial process for this paper, on which she is listed as an author. The other authors have declared that no conflict of interest exists.

Funding

This work was supported by a Medical Research Council Confidence in Concept Award to AT (MC_PC_15046), NIHR Senior Investigator Award to P M S (NF-SI-0514-10090), NIHR Leeds Biomedical Research Centre and NIHR Leeds In Vitro Diagnostic Evidence Co-operative.

Trial registration

Clinicaltrials.gov NCT03313297, www.isrctn.com ISRCTN74621291.

Data availability statement

All data associated with this study are available in the main text or the Supplementary materials.

Author contribution statement

RA: conceptualization, design, investigation, resources, supervision, writing – review and editing; E M A H: conceptualization, design, software, formal analysis, data curation, visualization, writing – review and editing; K S: design, investigation, writing – review and editing; F D G: conceptualization, investigation, writing – review and editing; A A: design, investigation, writing – review and editing; R J F: design, resources, supervision; L W: design, resources, supervision; L P: design, resources, supervision; A F: design, resources, supervision, writing – review and editing; A E T: design, investigation, writing – review and editing; W A: design, investigation, writing – review and editing; A W M: conceptualization, supervision, writing – review and editing; A A T: conceptualization, writing – review and editing; P M S: conceptualization, funding acquisition, writing – review and editing; D A R: design, investigation, supervision, writing – review and editing; A T: conceptualization, design, funding acquisition, investigation, project administration, supervision, validation, writing – original draft, writing – review and editing. All authors revised the article for critically important content and approved the final version to be published.

Acknowledgements

This paper presents independent research supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors thank Deborah Berlyne, PhD for her editorial support.

References

- 1 Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC & Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. *Wound Repair and Regeneration* 2009 **17** 763–771. (<https://doi.org/10.1111/j.1524-475X.2009.00543.x>)
- 2 Vowden K, Vowden P & Posnett J. The resource costs of wound care in Bradford and Airedale primary care trust in the UK. *Journal of Wound Care* 2009 **18** 93–94, 96–98, 100 passim. (<https://doi.org/10.12968/jowc.2009.18.3.39814>)
- 3 Hex N, Bartlett C, Wright D, Taylor M & Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. *Diabetic Medicine* 2012 **29** 855–862. (<https://doi.org/10.1111/j.1464-5491.2012.03698.x>)
- 4 Sowers JR & Lippman HR. Cushing's syndrome due to ectopic ACTH production: cutaneous manifestations. *Cutis* 1985 **36** 351–352, 354.
- 5 Autio P, Oikarinen A, Melkko J, Risteli J & Risteli L. Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. *British Journal of Dermatology* 1994 **131** 660–663. (<https://doi.org/10.1111/j.1365-2133.1994.tb04978.x>)
- 6 Werth VP, Kligman AM, Shi X & Pagnoni A. Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. *Archives of Dermatological Research* 1998 **290** 388–393. (<https://doi.org/10.1007/s004030050322>)
- 7 Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gasmueller J & Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin Pharmacology and Applied Skin Physiology* 2002 **15** 85–91. (<https://doi.org/10.1159/000049394>)
- 8 Nuutinen P, Riekkilä R, Parikka M, Salo T, Autio P, Risteli J & Oikarinen A. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. *British Journal of Dermatology* 2003 **148** 39–45. (<https://doi.org/10.1046/j.1365-2133.2003.05018.x>)
- 9 Lee B, Vouthounis C, Stojadinovic O, Brem H, Im M & Tomic-Canic M. From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing. *Journal of Molecular Biology* 2005 **345** 1083–1097. (<https://doi.org/10.1016/j.jmb.2004.11.027>)
- 10 Schoepe S, Schacke H, May E & Asadullah K. Glucocorticoid therapy-induced skin atrophy. *Experimental Dermatology* 2006 **15** 406–420. (<https://doi.org/10.1111/j.0906-6705.2006.00435.x>)
- 11 Aberg KM, Radek KA, Choi EH, Kim DK, Demerjian M, Hupe M, Kerbleski J, Gallo RL, Ganz T, Mauro T *et al.* Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. *Journal of Clinical Investigation* 2007 **117** 3339–3349. (<https://doi.org/10.1172/JCI31726>)
- 12 Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW & Lavery GG. 11 β -HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. *PNAS* 2014 **111** E2482–E2491. (<https://doi.org/10.1073/pnas.1323681111>)
- 13 Tiganescu A, Tahrani AA, Morgan SA, Otranto M, Desmouliere A, Abrahams L, Hassan-Smith Z, Walker EA, Rabbitt EH, Cooper MS *et al.* 11 β -Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. *Journal of Clinical Investigation* 2013 **123** 3051–3060. (<https://doi.org/10.1172/JCI64162>)

- 14 Tiganescu A, Walker EA, Hardy RS, Mayes AE & Stewart PM. Localization, age- and site-dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in skin. *Journal of Investigative Dermatology* 2011 **131** 30–36. (<https://doi.org/10.1038/jid.2010.257>)
- 15 Tiganescu A, Hupe M, Uchida Y, Mauro T, Elias PM & Holleran WM. Increased glucocorticoid activation during mouse skin wound healing. *Journal of Endocrinology* 2014 **221** 51–61. (<https://doi.org/10.1530/JOE-13-0420>)
- 16 Tiganescu A, Hupe M, Uchida Y, Mauro T, Elias PM & Holleran WM. Topical 11 beta-hydroxysteroid dehydrogenase type 1 inhibition corrects cutaneous features of systemic glucocorticoid excess in female mice. *Endocrinology* 2018 **159** 547–556. (<https://doi.org/10.1210/en.2017-00607>)
- 17 Terao M, Murota H, Kimura A, Kato A, Ishikawa A, Igawa K, Miyoshi E & Katayama I. 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. *PLoS ONE* 2011 **6** e25039. (<https://doi.org/10.1371/journal.pone.0025039>)
- 18 Youm JK, Park K, Uchida Y, Chan A, Mauro TM, Holleran WM & Elias PM. Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing. *Wound Repair and Regeneration* 2013 **21** 715–722. (<https://doi.org/10.1111/wrr.12083>)
- 19 Bitar MS. Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. *American Journal of Pathology* 1998 **152** 547–554.
- 20 Steptoe A, Hackett RA, Lazzarino AI, Bostock S, La Marca R, Carvalho LA & Hamer M. Disruption of multisystem responses to stress in type 2 diabetes: investigating the dynamics of allostatic load. *PNAS* 2014 **111** 15693–15698. (<https://doi.org/10.1073/pnas.1410401111>)
- 21 Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceutical Statistics* 2005 **4** 287–291. (<https://doi.org/10.1002/pst.185>)
- 22 Lee EC, Whitehead AL, Jacques RM & Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? *BMC Medical Research Methodology* 2014 **14** 41. (<https://doi.org/10.1186/1471-2288-14-41>)
- 23 Sagmeister MS, Taylor AE, Fenton A, Wall NA, Chanouzas D, Nightingale PG, Ferro CJ, Arlt W, Cockwell P, Hardy RS *et al.* Glucocorticoid activation by 11 beta-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: a cross-sectional study. *Clinical Endocrinology* 2019 **90** 241–249. (<https://doi.org/10.1111/cen.13889>)
- 24 van Smeden J, Janssens M, Gooris GS & Bouwstra JA. The important role of stratum corneum lipids for the cutaneous barrier function. *Biochimica et Biophysica Acta* 2014 **1841** 295–313. (<https://doi.org/10.1016/j.bbali.2013.11.006>)
- 25 Lin TK, Man MQ, Santiago JL, Scharschmidt TC, Hupe M, Martin-Ezquerro G, Youm JK, Zhai Y, Trullas C, Feingold KR *et al.* Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated. *Journal of Investigative Dermatology* 2014 **134** 2890–2897. (<https://doi.org/10.1038/jid.2014.265>)
- 26 Seite S, Khemis A, Rougier A & Ortonne JP. Importance of treatment of skin xerosis in diabetes. *Journal of the European Academy of Dermatology and Venereology* 2011 **25** 607–609. (<https://doi.org/10.1111/j.1468-3083.2010.03807.x>)
- 27 Vinik AI, Nevoret ML & Casellini C. The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. *Frontiers in Endocrinology* 2015 **6** 94. (<https://doi.org/10.3389/fendo.2015.00094>)
- 28 Hardy RS, Botfield H, Markey K, Mitchell JL, Alimajstorovic Z, Westgate CSJ, Sagmeister M, Fairclough RJ, Ottridge RS, Yiangou A *et al.* 11betaHSD1 inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension. *Journal of Clinical Endocrinology and Metabolism* 2021 **106** 174–187. (<https://doi.org/10.1210/clinem.dgaa766>)
- 29 Schwab D, Sturm C, Portron A, Fuerst-Recktenwald S, Hainzl D, Jordan P, Stewart WC, Tepedino ME & DuBiner H. Oral administration of the 11beta-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study. *BMJ Open Ophthalmology* 2017 **1** e000063. (<https://doi.org/10.1136/bmjophth-2016-000063>)
- 30 Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E & Kaufman KD. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. *Diabetes, Obesity and Metabolism* 2011 **13** 498–504. (<https://doi.org/10.1111/j.1463-1326.2011.01375.x>)
- 31 Heise T, Morrow L, Hompesch M, Haring HU, Kapitza C, Abt M, Ramsauer M, Magnone MC & Fuerst-Recktenwald S. Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 2014 **16** 1070–1077. (<https://doi.org/10.1111/dom.12317>)
- 32 Freude S, Heise T, Woerle HJ, Jungnik A, Rauch T, Hamilton B, Scholch C, Huang F & Graefe-Mody U. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks. *Diabetes, Obesity and Metabolism* 2016 **18** 483–490. (<https://doi.org/10.1111/dom.12635>)
- 33 Palermo M, Shackleton CH, Mantero F & Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. *Clinical Endocrinology* 1996 **45** 605–611. (<https://doi.org/10.1046/j.1365-2265.1996.00853.x>)
- 34 Greaves NS, Benatar B, Whiteside S, Alonso-Rasgado T, Baguneid M & Bayat A. Optical coherence tomography: a reliable alternative to invasive histological assessment of acute wound healing in human skin? *British Journal of Dermatology* 2014 **170** 840–850. (<https://doi.org/10.1111/bjd.12786>)
- 35 Wang Y, Ajjan R, Freeman A, Stewart P, Galdo FD & Tiganescu A. Volumetric quantification of wound healing by machine learning and optical coherence tomography in adults with type 2 diabetes: the GC-SHEALD RCT. *medRxiv* 2021. (<https://doi.org/10.1101/2021.06.30.21259754>)
- 36 Harris E, Tiganescu A, Tubeuf S & Mackie SL. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. *Current Rheumatology Reports* 2015 **17** 513. (<https://doi.org/10.1007/s11926-015-0513-4>)
- 37 Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR & Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. *Journal of Clinical Investigation* 1995 **95** 2281–2290. (<https://doi.org/10.1172/JCI117919>)
- 38 Choe SJ, Kim D, Kim EJ, Ahn JS, Choi EJ, Son ED, Lee TR & Choi EH. Psychological stress deteriorates skin barrier function by activating 11beta-hydroxysteroid dehydrogenase 1 and the HPA axis. *Scientific Reports* 2018 **8** 6334. (<https://doi.org/10.1038/s41598-018-24653-z>)
- 39 Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM & Feingold KR. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. *Journal of Investigative Dermatology* 2003 **120** 456–464. (<https://doi.org/10.1046/j.1523-1747.2003.12053.x>)
- 40 Kolbe L, Kligman AM, Schreiner V & Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. *Skin Research and Technology* 2001 **7** 73–77. (<https://doi.org/10.1034/j.1600-0846.2001.70203.x>)
- 41 Ahn SK, Bak HN, Park BD, Kim YH, Youm JK, Choi EH, Hong SP & Lee SH. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. *Journal of Dermatology* 2006 **33** 80–90. (<https://doi.org/10.1111/j.1346-8138.2006.00018.x>)

- 42 Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G, Agostini C, Cappellari R *et al*. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. *Basic Research in Cardiology* 2013 **108** 313. (<https://doi.org/10.1007/s00395-012-0313-1>)
- 43 Uto A, Miyashita K, Endo S, Sato M, Ryuzaki M, Kinouchi K, Mitsuishi M, Meguro S & Itoh H. Transient dexamethasone loading induces prolonged hyperglycemia in male mice with histone acetylation in Dpp-4 promoter. *Endocrinology* 2021 **162** bqab193. (<https://doi.org/10.1210/endoqr/bqab193>)
- 44 Carolina E, Kato T, Khanh VC, Moriguchi K, Yamashita T, Takeuchi K, Hamada H & Ohneda O. Glucocorticoid impaired the wound healing ability of endothelial progenitor cells by reducing the expression of CXCR4 in the PGE2 pathway. *Frontiers in Medicine* 2018 **5** 276. (<https://doi.org/10.3389/fmed.2018.00276>)
- 45 Fadini GP, Menegazzo L, Rigato M, Scattolini V, Poncina N, Bruttocao A, Ciciliot S, Mammano F, Ciobotaru CD, Brocco E *et al*. NETosis delays diabetic wound healing in mice and humans. *Diabetes* 2016 **65** 1061–1071. (<https://doi.org/10.2337/db15-0863>)
- 46 Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV *et al*. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care* 2010 **33** 1516–1522. (<https://doi.org/10.2337/dc09-2315>)
- 47 Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB & Feig PU. Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. *Journal of the American Society of Hypertension* 2011 **5** 166–176. (<https://doi.org/10.1016/j.jash.2011.01.009>)
- 48 Armstrong DG, Boulton AJM & Bus SA. Diabetic foot ulcers and their recurrence. *New England Journal of Medicine* 2017 **376** 2367–2375. (<https://doi.org/10.1056/NEJMra1615439>)
- 49 Young MJ, McCardle JE, Randall LE & Barclay JI. Improved survival of diabetic foot ulcer patients 1995–2008: possible impact of aggressive cardiovascular risk management. *Diabetes Care* 2008 **31** 2143–2147. (<https://doi.org/10.2337/dc08-1242>)

Received 30 November 2021

Revised version received 27 January 2022

Accepted 3 February 2022